Prognostic Factors Influencing the Patency of Hemodialysis Vascular Access: Literature Review and Novel Therapeutic Modality by Far Infrared Therapy

Chih-Ching Lin[1,2]*, Wu-Chang Yang[1,2]

[1]*National Yang-Ming University School of Medicine, and* [2]*Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.*

In Taiwan, more than 85% of patients with end-stage renal disease undergo maintenance hemodialysis (HD). The native arteriovenous fistula (AVF) accounts for a prevalence of more than 80% of the vascular access in our patients. Some mechanical factors may affect the patency of hemodialysis vascular access, such as surgical skill, puncture technique and shear stress on the vascular endothelium. Several medical factors have also been identified to be associated with vascular access prognosis in HD patients, including stasis, hypercoagulability, endothelial cell injury, medications, red cell mass and genotype polymorphisms of transforming growth factor-β1 and methylene tetrahydrofolate reductase. According to our previous study, AVF failure was associated with a longer dinucleotide $(GT)_n$ repeat ($n \geq 30$) in the promoter of the heme oxygenase-1 (HO-1) gene. Our recent study also demonstrated that far-infrared therapy, a noninvasive and convenient therapeutic modality, can improve access flow, inflammatory status and survival of the AVF in HD patients through both its thermal and non-thermal (endothelial-improving, anti-inflammatory, antiproliferative, antioxidative) effects by upregulating NF-E2-related factor-2-dependent HO-1 expression, leading to the inhibition of expression of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1. [*J Chin Med Assoc* 2009;72(3): 109–116]

Key Words: far-infrared therapy, genotype polymorphism, heme oxygenase-1, hemodialysis, vascular access

Introduction

In Taiwan, more than 85% of patients with end-stage renal disease (ESRD) undergo maintenance hemodialysis (HD). A well-functioning vascular access is necessary for HD. There are 3 main types of long-term vascular access for hemodialysis: (1) the cuffed and tunneled double-lumen catheter; (2) the polytetrafluoroethylene (PTFE) arteriovenous graft (AVG); and (3) the native arteriovenous fistula (AVF). Each of the 3 types of HD vascular access has its own advantages and disadvantages.[1] AVF is the preferred form of HD vascular access on account of its lower risk of infection and thrombosis.[2] Since long-term technical survival is best for native AVF, it accounts for more than 80% of

all the vascular accesses in HD patients in Taiwan. With the use of Medicare data, about 17–25% of HD patient hospitalizations in the United States result from vascular access complications, at a cost of $1 billion annually.[3] Failure of dialysis access can result from either inadequate blood flow on account of stenosis of the venous outflow tract or complete occlusion due to thrombosis.[4] About 80–85% of arteriovenous (AV) access failures come from AV access thromboses, more than 80% of which result from AVF stenoses.[4,5] Decreased access flow is associated with an increased risk of access thrombosis. Access flow (Qa) $< 500\,mL/min$ was demonstrated to be predictive of poorer unassisted patency of native AVF by variable pump flow-based Doppler ultrasound method in our previous

109

study,[6] which showed that the unassisted patency of vascular access at 6 months was significantly poorer in patients with $Qa < 500$ mL/min than in those with $Qa \geq 500$ mL/min (13.6% *vs.* 92.2%; $p < 0.0001$). In addition to access flow, some mechanical factors influence AVF patency, such as the surgical skill, the puncture technique, and the shear stress on the vascular endothelia.

Medical Factors Contributing to Malfunction of HD Vascular Access

As shown in Table 1, several medical factors have been identified to be associated with vascular access stenosis in HD patients, including stasis, hypercoagulability, endothelial cell injury, medications, and red cell mass.[7]

Stasis
Any cause of lower blood flow may predispose the vascular access to stasis, which is an important component of Virchow's triad.

Hypotension
Intradialytic hypotension is connected with intravascular blood volume, which is quite variable for each patient.[8] Regardless of the cause of hypotension, it results in a reduction in access flow, making it more susceptible to thrombosis.

Hypoalbuminemia
Hypoalbuminemia is related to a higher rate of thrombosis in PTFE AVG,[9] especially in malnourished patients as well as in cirrhotics.

Compression
Inappropriate compression of the vascular access after HD may be associated with excessive direct pressure applied by the patient or nursing staff on a vascular access or by accident during sleep.

Hypercoagulable states
Antiphospholipid antibodies
Antiphospholipid antibodies include lupus anticoagulant and anticardiolipin antibodies. ESRD patients in general have been shown to have an elevated amount of circulating antiphospholipid antibodies, and this amount increases even more for those patients on HD.[10] Lupus anticoagulant was shown to be associated with access thrombosis,[11] whereas anticardiolipin antibodies were associated with recurrent access thrombosis.[12] However, prospective studies are needed to determine the association with vascular access thrombosis.

Hyperhomocysteinemia
The common risk factor for both deep venous thrombosis and atherosclerosis is homocysteine, which might cause endothelial dysfunction, leading to impaired thrombolytic capacity and vasodilation of vascular

Table 1. Prognostic factors affecting patency of hemodialysis vascular access

Mechanical factors

Surgical skill

Technique of puncture vascular access

Shear stress on the vascular endothelia

Medical factors

Stasis: hypotension, hypoalbuminemia, compression

Hypercoagulable states: antiphospholipid antibodies, hyperhomocysteinemia, factor V leiden, lipoprotein(a)

Endothelial cell injury: preexisting intimal hyperplasia, TNF-α, oxidative stress, calcium phosphate deposition, activated platelets

Medications: ACEI ($\uparrow$2° patency in AVF), CCB ($\uparrow$1° patency in AVG), aspirin ($\uparrow$2° patency in AVG), dipyridamole ($\uparrow$AVG patency), warfarin ($\downarrow$1° patency in AVG)

Genotype polymorphisms with poor patency of AVF:
    TGF-β1: high-producer haplotypes (+869/+915: TC/GG and TT/GG)
    MTHFR: T allele of MTHFR C677T
    HO-1: a longer length polymorphism with GT repeat number ≥ 30

Lower access flow: < 500 mL/min for AVF, < 600 mL/min for AVG

Others: higher RBC mass, less exercise, late referral, infection, DM, smoking

Physical therapy: far-infrared therapy

TNF-α = tumor necrosis factor-α; ACEI = angiotensin-converting enzyme inhibitor; $\uparrow$ = increased; 2° = secondary; AVF = arteriovenous fistula; CCB = calcium channel blocker; 1° = primary; AVG = arteriovenous graft; $\downarrow$ = decreased; TGF-β1 = transforming growth factor-β1; MTHFR = methylene tetrahydrofolate reductase; HO-1 = heme oxygenase-1; RBC = red blood cell; DM = diabetes mellitus.

endothelium,[13] and increased vascular smooth muscle cell (VSMC) proliferation.[14] Fukasawa et al showed that the genotype polymorphism responsible for hyperhomocysteinemia was associated with a higher risk of AVF thrombosis.[15] Some studies could not demonstrate the relationship between hyperhomocysteinemia and vascular access thrombosis.[16,17] A prospective study showed that hyperhomocysteinemia was associated with a 4% increased risk of vascular access failure.[18] It was also shown that increased homocysteine levels could cause VSMC proliferation, while folic acid supplementation inhibited this homocysteine-induced proliferation.[19] Treatment of hyperhomocysteinemia with oral folate has shown various results. Some studies observed that there was no significant effect of folate at doses of 1–5 mg/day, while others showed a significant decrease.[20] Bostom et al showed that a daily 15 mg dose of folic acid could lower plasma homocysteine levels in only one third of patients.[21] The best factor predicting response to folate is the baseline homocysteine levels, and higher doses of folate of 30–60 mg/day were only more effective than 15 mg/day in patients with the methylene tetrahydrofolate reductase (MTHFR) 677TT genotype.[22] More studies are needed to identify whether decreasing homocysteine levels in HD patients can result in a significant reduction of vascular access thrombosis.

Factor V leiden

A mutation at nucleotide position 1691 of the factor V gene leads to the formation of factor V leiden, which was associated with peripheral vascular graft thrombosis due to hypercoagulability on account of resistance to activated protein C.[23] Patients with homozygous mutation of the factor V gene have a higher risk of developing vascular access thrombosis than those with heterozygous mutation.

Lipoprotein(a)

Association of lipoprotein(a) with atherothrombotic complications was reported in both the general and ESRD populations but with equivocal results.[24,25] It was shown to be a risk factor for thrombosis in either white or black patients, but the power in race-specific analyses was inadequate in both studies.

Endothelial cell injury

Many factors lead to endothelial cell injury or dysfunction and they are listed as follows.

Preexisting intimal hyperplasia

Preexisting intimal hyperplasia is an important cause of inadequate radial artery diameter, and histologic examination revealed that this is quite common in patients undergoing HD. Only diabetes and age are risk factors for preexisting intimal hyperplasia. Intimal hyperplasia of preexisting radial artery is also associated with a lower frequency of 1-year patency of AVFs.[26]

Tumor necrosis factor-α (TNF-α)

Leukocytes release TNF-α, which could induce proliferation of vascular smooth muscles leading to subsequent intimal hyperplasia. The interaction between PTFE AVGs and circulating peripheral blood mononuclear cells located upstream of the venous anastomosis potentiates the release of TNF-α.[27]

Oxidative stress

Oxidative hyperactivity in the uremic status usually leads to an increased amount of circulating and tissue inflammatory molecules.[28] Interaction with dialysis membranes have also been reported as an important cause leading to oxidative stress, resulting in an increased expression of endothelin-1, which has been associated with intimal hyperplasia and smooth muscle cell vasoconstriction. Transforming growth factor-β and platelet-derived growth factor have also been implicated in intimal hyperplasia but seem to be clustered at the venous end of the failed AV access.

Calcium phosphate deposition

Stenosis of AVFs were associated with calcium phosphate deposition, which is mainly in the form of calcium apatite. Brushite, another calcium phosphate precipitate, may be formed under acidic conditions and be found in stenotic AVFs, but it was not present in non-stenotic AVFs and normal veins (non-AVF).[29] More studies are needed to identify whether brushite is the cause or a result of vascular access dysfunction.

Activated platelets

Injury to endothelial cells exposes the basement membrane and extracellular matrix leading to activation of platelets. It has been shown that higher levels of circulating activated platelets are associated with shorter survival of AV access. Inhibition of platelet activation with aspirin and sulfinpyrazone has been shown to prevent recurrent access thrombosis.[30]

Medications

The largest study evaluating the effects of specific medications on AV access patency is the Dialysis Outcomes and Practice Patterns Study (DOPPS).[31] This prospective, international study observed 900 AVFs and 1,944 AVGs, and excluded failure of AV accesses within 30 days due to technical failure. There were

some informative results. The primary patency of AVFs was not improved by any drug, and only angiotensin-converting enzyme inhibitors improved secondary patency. Calcium channel blockers improved primary patency of AVGs, and aspirin improved secondary patency. Warfarin reduced primary graft patency, although this may be due to deficiency of protein C or S. Another study showed that dipyridamole alone was associated with a significant risk reduction for AVG thrombosis, while aspirin did not improve the risk of thrombosis.[32] In addition, calcium channel blockers have been shown to inhibit neointimal hyperplasia in AVGs.[33]

Red blood cell mass

According to the report by the Canadian Erythropoietin Group, the incidence of vascular access thrombosis was significantly increased in those patients receiving erythropoietin.[34] Churchill et al showed that erythropoietin was not related to access thrombosis; however, their study was not double-blinded.[35] More double-blinded, placebo-controlled, randomized trials are needed to determine the role of erythropoietin in AV access patency.

Exercise

Leaf et al reported that an isometric exercise training program could increase the diameter of the cephalic vein, theoretically increasing the possibility of creation of an AVF.[36] More studies are needed to evaluate the effect of exercise on patency rates.

Timely referral

Timely referral to nephrologists enables more precise prediction of the appropriate timing for the placement of a fistula or graft and the initiation of dialysis, which could help HD patients avoid implantation of any temporary catheter access. Not only would this avoid the complications related to catheter placement, but it would also reduce the frequency of AV access failure.[37] Chesser and Baker reported that early referral to a nephrologist was associated with a higher frequency of patients starting HD on a functioning AVF and lower overall mortality.[38]

Infection

About 50% of vascular access infections are caused by *Staphylococcus epidermidis*, with Gram-negative organisms accounting for approximately 23%.[39] *Staphylococcus aureus* accounts for about 20% of infections, and is more likely than *S. epidermidis* to lead to bacteremia. In addition, sources of bacterial seeding to AVGs may come from sites other than dialysis punctures, such as infective endocarditis, intravenous route used by drug abuser or intra-abdominal abscess.

Cardiovascular risk factors

Certain demographic characteristics have been implicated in AV access failure. Smoking, a risk factor for atherosclerosis in general, is associated with both early and late fistula failure. Diabetes has also consistently been associated with access failure in prospective studies, possibly due to an increase in VSMC proliferation.[40]

Genotype Polymorphisms and AVF Malfunction

Transforming growth factor-β1 (TGF-β1)

The pathologic features of vascular access stenosis are composed of intimal hyperplasia, VSMC proliferation in the media with subsequent migration to intima, and excessive accumulation of extracellular matrix,[28] which are mediated by several growth factors such as TGF-β1. The synthesis of TGF-β1 interindividually differs due to the 2 single nucleotide polymorphisms in the DNA sequence encoding the signal sequence of the TGF-β1 protein, located at position +869 (codon 10, T > C, leucin > proline) and position +915 (codon 25, G > C, arginine > proline). Three different cytokine-producer types are distinguished: high-producer haplotypes are TC (codon 10)/GG (codon 25) and TT/GG; intermediate-producer haplotypes are CC/GG, TC/GC, and TT/GC; and low-producer haplotypes are CC/CC, CC/GC, TT/CC, and TC/CC, respectively. AVF patency was significantly associated with the TGF-β1 genotype; patencies were 62.4% and 81.2% after 12 months for TGF-β1 high and intermediate producers, respectively.[41]

MTHFR

The MTHFR C677T polymorphism has been reported to be closely related to plasma homocysteine level. Percentages of patients who experienced AVF malfunction were as follows: CC (12.6%), CT (20.3%), and TT (31.8%). The number of those who experienced obstruction was significantly larger with TT than CC ($p < 0.01$). The odds ratio of genetic polymorphisms predicting AVF malfunction is 1.77 for T allele-containing genotypes of MTHFR.[15]

Heme oxygenase-1 (HO-1)

HO-1 is another factor associated with higher risk of developing some vascular diseases. HO plays a crucial role in controlling intracellular heme levels by catalyzing the rate-limiting step in the metabolism of heme. HO cleaves the α-meso carbon bridge of heme, producing equimolar quantities of carbon monoxide (CO),

biliverdin, and free iron.[42] Biliverdin is subsequently metabolized to bilirubin by biliverdin reductase, and free iron is promptly sequestered by ferritin. There are 3 distinct isoenzymes of HO (HO-1, HO-2, HO-3).[43–45] HO-1 is an inducible 32-kDa protein that is ubiquitously distributed and is located at chromosome 22q12.[46] HO-1 induction stimulates cell cycle progression and proliferation in vascular endothelium,[47] but inhibits the growth of VSMCs via the release of CO. The mechanisms of CO-mediated apoptosis in VSMCs include: (1) increase of p53 expression, which is a proapoptotic protein; (2) release of cytochrome c from the mitochondria;[48] and (3) release of biliverdin and bilirubin, which at high concentrations are known inducers of apoptosis.[49]

Length polymorphisms in the dinucleotide GT repeats

A (GT)$_n$ dinucleotide repeat with various length was identified in the proximal promoter region.[50] It functions as a negative regulatory region and is located between −198 and −258 of the human HO-1 promoter. Individuals with shorter repeats (≤25) demonstrate higher levels of HO-1, whereas individuals with longer repeats (>25) have lower levels of HO-1.[51]

HO-1 length polymorphisms and cardiovascular diseases

Length polymorphisms of GT repeat in the promoter region of the HO-1 gene vary between subjects and correlate with disease activity. It was reported that a longer length polymorphism of GT repeat (>25 or 27 or 30) in HO-1 promoter was associated with susceptibility to the following conditions: restenosis and increased vascular inflammation after percutaneous transluminal angioplasty,[52,53] coronary artery disease in type 2 diabetic patients,[54] Japanese patients with coronary risk factors,[55] and abdominal aortic aneurysms.[56]

Long GT repeat in HO-1 promoter and poor AVF patency (Figure 1)

In our study,[57] 603 HD patients were enrolled; 178 had history of AVF failure, while 425 did not. After correction for many factors (such as age, sex, HD duration, underlying cause of ESRD), a significantly higher frequency of AVF failure was still noted for the L/L and L/S genotypes of HO-1, with a hazard ratio of 2.040 when compared with the S/S genotype. The proportion of AVF failure increased from 20.3% for the S/S genotype to 31.0% for the L/S genotype and 35.4% for the L/L genotype. The unassisted patencies of AVF at 5 years decreased significantly from 83.8% to 75.1% and 69% in S/S, L/S and L/L genotypes, respectively.


Figure 1. Summary of our study addressing the roles of heme oxygenase-1 (HO-1) and far-infrared therapy in the regulation of AVF function. The main results of our study are: (1) an association of shorter dinucleotide GT repeat length polymorphisms (GT)$_n$ of HO-1 gene promoter with higher patency of AVF in hemodialysis patients; (2) a beneficial effect of far-infrared therapy on hemodynamic parameters (including access flow, cardiac output) and patency of vascular access in hemodialysis patients; and (3) a stimulating effect of HO-1 expression by far-infrared therapy.

Far-infrared Therapy Improves AVF Patency Through Upregulation of HO-1 Expression (Figure 1)

Introduction
Infrared radiation is an invisible electromagnetic wave with a longer wavelength than that of visible light. According to the difference in wavelength, infrared radiation can be divided into 3 categories: near-infrared radiation (0.8–1.5 μm); middle-infrared radiation (1.5–5.6 μm); and far-infrared (FIR) radiation (5.6–1,000 μm).[58] Infrared radiation transfers energy that is perceived as heat by thermoreceptors in the skin.[59]

Clinical applications
The application of FIR radiation includes food preservation[60] and health promotion.[61,62] Animal studies have demonstrated that FIR improves skin blood flow,[63,64] leading to the use of FIR in the treatment of ischemic lesions and necrosis of skin tissue due to trauma, diabetes mellitus and peripheral arterial-occlusive disease. In addition, some studies indicate that FIR therapy may improve endothelial function and reduce the frequency of some cardiovascular diseases, including improving endothelial dysfunction in patients with coronary risk factors, heart failure and arrhythmia.[65–67]

FIR therapy improves access flow and unassisted patency of AVF in HD patients (Figure 1)
In our previous study,[68] a total of 145 HD patients were enrolled, with 73 in the control group and 72 in the FIR group. The Qa$_1$/Qa$_2$ and Qa$_3$/Qa$_4$ were

defined as the Qa measured at the beginning, at 40 minutes later in the HD session prior to the initiation, and at the end of the study, respectively. The incremental change in Qa in the single HD session with FIR therapy was significantly higher than in that without FIR therapy (13.2 ± 114.7 mL/min *vs.* -33.4 ± 132.3 mL/min). Compared with controls, patients receiving FIR therapy for a year had: (1) lower incidence (12.5% *vs.* 30.1%) of AVF malfunction; (2) higher values of incremental change in access flow; and (3) better unassisted patency of AVF (85.9% *vs.* 67.6%).

Mechanisms of FIR therapy

Our results indicate that both short-term and long-term FIR can increase access flow. Moreover, there is an additive benefit of both short- and long-term effects. The short-term thermal effect of FIR results in vasodilatation and increasing Qa. According to the report by Hartel et al, the temperature can be increased up to 4°C in 10 mm depth of tissue.[69] In addition, infrared therapy may allow multiple energy transfers as deep as 2–3 cm into subcutaneous tissue without irritating or overheating the skin like unfiltered heat radiation.[69] The skin temperature steadily increased to a plateau around 38–39°C during FIR treatment for 30–60 minutes as long as the distance between the ceramic plate and the skin was more than 20 cm.[63]

In addition to the short-term thermal effect, the increase in both Qa and fistula patency in this study may result from the long-term (accumulated thermal and non-thermal) effect of FIR therapy. In particular, FIR may improve endothelial function, which was observed not only in animal studies[63,64,66] but also in one clinical study.[65] Yu et al suggest that the beneficial effect of FIR therapy on skin blood flow may be related to L-arginine/nitric oxide pathway.[63] Akasaki et al found that repeated FIR therapy could upregulate eNOS expression and augment angiogenesis in an apolipoprotein E-deficient mouse model of unilateral hind limb ischemia.[64] Moreover, Ikeda et al reported that 4 weeks of sauna therapy significantly increased serum nitrate concentrations as well as the expression of mRNA and protein of eNOS in the aortas of TO-2 hamsters.[66] In addition, Imamura et al showed that 2 weeks of repeated sauna therapy significantly improved vascular endothelial function, resulting in an increase in flow-mediated endothelium-dependent dilatation of the brachial artery from 4% to 5.8% in patients with coronary risk factors.[65]

Our recent study also showed that FIR induced expression of HO-1 via stimulating NF-E2-related factor-2 (Nrf2)-dependent promoter activity, with the maximal time-course effect on the expression of HO-1

and Nrf2 both at 6 hours.[70] Tumor necrosis factor-α (TNF-α)-induced expression of E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular cell adhesion molecule-1 (ICAM-1) were maximally suppressed by FIR therapy at 4, 6 and 24 hours, respectively. Higher expression of HO-1 may explain the antiproliferative and anti-inflammatory effect of FIR therapy.

Besides activating expression of eNOS and HO-1, inhibiting neointimal hyperplasia and decreasing oxidative stress are 2 other non-thermal effects of FIR therapy. Kipshidze et al found that nonablative infrared laser therapy inhibited neointimal hyperplasia after PTCA in cholesterol-fed rabbits for up to 60 days due to suppression of the growth of VSMCs.[71] In addition, Masuda et al[72] showed that patients receiving FIR dry sauna for 45 minutes a day for 2 weeks had lower systolic blood pressure and urinary levels of 8-epi-prostaglandin $F_{2\alpha}$, which is a chemically stable product of lipid peroxidation, and the level has been suggested to be a reliable marker of oxidative stress *in vivo*.[73]

In conclusion, many factors may affect the prognosis of vascular access. FIR therapy, a noninvasive and convenient therapeutic modality, can improve Qa, inflammatory status and survival of the AVF in HD patients through both its thermal and the above-mentioned non-thermal (anti-inflammatory) effects by upregulating Nrf2-dependent HO-1 expression, leading to the inhibition of E-selectin, VCAM-1 and ICAM-1 expression.

References

1. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. *J Am Soc Nephrol* 2006;17:1112–27.
2. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, Meyer K, et al. Vascular access for hemodialysis. *Kidney Int* 1999;55:2078–90.
3. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. *J Am Soc Nephrol* 1996;7:523–35.
4. Paun M, Beach K, Ahmad S, Hickman R, Meissner M, Plett C, Strandness DE Jr, et al. New ultrasound approaches to dialysis access monitoring. *Am J Kidney Dis* 2000;35:477–81.
5. Windus DW. Permanent vascular access: a nephrologist's view. *Am J Kidney Dis* 1993;21:457–71.
6. Lin CC, Chang CF, Chiou HJ, Sun YC, Chiang SS, Lin MW, Lee PC, et al. Variable pump flow-based Doppler ultrasound method: a novel approach to the measurement of access flow in hemodialysis patients. *J Am Soc Nephrol* 2005;16: 229–36.
7. Abularrage CJ, Sidawy AN, Weiswasser JM, White PW, Arora S. Medical factors affecting patency of arteriovenous access. *Semin Vasc Surg* 2004;17:25–31.
8. Barth C, Boer W, Garzoni D, Kuenzi T, Ries W, Schaefer R, Schneditz D, et al. Characteristics of hypotension-prone

haemodialysis patients: is there a critical relative blood volume? *Nephrol Dial Transplant* 2003;18:1353–60.

9. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. *Am J Kidney Dis* 2000;36:68–74.

10. Haviv YS. Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? *Nephron* 2000;86:447–54.

11. Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. *Kidney Int* 1995;48:794–800.

12. Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. *Am J Kidney Dis* 1995;26:347–52.

13. McCully KS. Homocysteine and vascular disease. *Nat Med* 1996;2:386–9.

14 Rajkumar V, Ragatzki P, Sima A, Levy J. Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: implications for therapy. *Endocrine* 1999;11:57–60.

15. Fukasawa M, Matsushita K, Kamiyama M, Mikami Y, Araki I, Yamagata Z, Takeda M. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. *Am J Kidney Dis* 2003; 41:637–42.

16. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. *Kidney Int* 1999;55:315–20.

17. Hojs R, Gorenjak M, Ekart R, Dvorsak B, Pecovnik-Balon B. Homocysteine and vascular access thrombosis in hemodialysis patients. *Ren Fail* 2002;24:215–22.

18. Shemin D, Lapane KL, Bausserman L, Kanaan E, Kahn S, Dworkin L, Bostom AG. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. *J Am Soc Nephrol* 1999;10:1095–9.

19. Carmody BJ, Arora S, Avena R, Cosby K, Sidawy AN. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. *J Vasc Surg* 1999;30:1121–8.

20. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? *Circulation* 2000;102:871–5.

21. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. *Kidney Int* 1996; 49:147–52.

22. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzenberger B, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. *J Am Soc Nephrol* 2000;11:1106–16.

23. Sampram ES, Lindblad B. The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions. *Eur J Vasc Endovasc Surg* 2001;22:134–8.

24. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. *JAMA* 1994;271: 999–1003.

25. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. *Circulation* 1992; 86:475–82.

26. Kim YO, Song HC, Yoon SA, Yang CW, Kim NI, Choi YJ, Lee EJ, et al. Preexisting intimal hyperplasia of radial artery is associated with early failure of radiocephalic arteriovenous fistula in hemodialysis patients. *Am J Kidney Dis* 2003;41:422–8.

27. Mattana J, Effiong C, Kapasi A, Singhal PC. Leukocyte-polytetrafluoroethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-alpha secretion. *Kidney Int* 1997;52:1478–85.

28. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. *Am J Kidney Dis* 2001;37:970–80.

29. Olsson LF, Odselius R, Ribbe E, Hegbrant J. Evidence of calcium phosphate depositions in stenotic arteriovenous fistulas. *Am J Kidney Dis* 2001;38:377–83.

30. Chuang YC, Chen JB, Yang LC, Kuo CY. Significance of platelet activation in vascular access survival of haemodialysis patients. *Nephrol Dial Transplant* 2003;18:947–54.

31. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 2002;40:1255–63.

32. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Antiplatelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. *Kidney Int* 1994;45:1477–83.

33. Huang P, Hawthorne WJ, Peng A, Angeli GL, Medbury HJ, Fletcher JP. Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. *Am J Surg* 2001;181:492–8.

34. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. *BMJ* 1990; 300:573–8.

35. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. *J Am Soc Nephrol* 1994; 4:1809–13.

36. Leaf DA, MacRae HS, Grant E, Kraut J. Isometric exercise increases the size of forearm veins in patients with chronic renal failure. *Am J Med Sci* 2003;325:115–9.

37. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen W Jr. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. *J Clin Epidemiol* 2002;55:711–6.

38. Chesser AM, Baker LR. Temporary vascular access for first dialysis is common, undesirable and usually avoidable. *Clin Nephrol* 1999;51:228–32.

39. Saeed Abdulrahman I, Al-Mueilo SH, Bokhary HA, Ladipo GO, Al-Rubaish A. A prospective study of hemodialysis access-related bacterial infections. *J Infect Chemother* 2002;8:242–6.

40. Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL. Longitudinal comparison of dialysis access methods: risk factors for failure. *J Vasc Surg* 1997;26:1009–19.

41. Heine GH, Ulrich C, Sester U, Sester M, Kohler H, Girndt M. Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. *Kidney Int* 2003;64:1101–7.

42. Maines MD. The heme oxygenase system: a regulator of second messenger gases. *Annu Rev Pharmacol Toxicol* 1997;37: 517–54.

43. Maines MD, Trakshel GM, Kutty RK. Characterization of two constitutive forms of rat liver microsomal heme oxygenase: only one molecular species of the enzyme is inducible. *J Biol Chem* 1986;261:411–9.

44. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. *FASEB J* 1988;2:2557–68.

45. McCoubrey WK Jr, Huang TJ, Maines MD. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. *Eur J Biochem* 1997;247: 725–32.

46. Durante W. Heme oxygenase-1 in growth control and its clinical application to vascular disease. *J Cell Physiol* 2003;195:373–82.

47. Deramaudt BM, Braunstein S, Remy P, Abraham NG. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. *J Cell Biochem* 1998; 68:121–7.

48. Liu XM, Chapman GB, Peyton KJ, Schafer AI, Durante W. Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. *Cardiovasc Res* 2002;55:396–405.

49. Silva RF, Rodrigues CM, Brites D. Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic acid but prevented by ursodeoxycholic acid. *J Hepatol* 2001; 34:402–8.

50. Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. *Proc Natl Acad Sci USA* 1994; 91:5987–91.

51. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. *Am J Hum Genet* 2000;66:187–95.

52. Exner M, Schillinger M, Minar E, Mlekusch W, Schlerka G, Haumer M, Mannhalter C, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. *J Endovasc Ther* 2001;8:433–40.

53. Schillinger M, Exner M, Mlekusch W, Ahmadi R, Rumpold H, Mannhalter C, Wagner O, et al. Heme oxygenase-1 genotype is a vascular anti-inflammatory factor following balloon angioplasty. *J Endovasc Ther* 2002;9:385–94.

54. Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. *Hum Genet* 2002;111:1–8.

55. Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, Aizawa T, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. *Arterioscler Thromb Vasc Biol* 2002;22:1680–5.

56. Schillinger M, Exner M, Mlekusch W, Domanovits H, Huber K, Mannhalter C, Wagner O, et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. *Thromb Res* 2002;106:131–6.

57. Lin CC, Yang WC, Lin SJ, Chen TW, Lee WS, Chang CF, Lee PC, et al. Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. *Kidney Int* 2006;69:165–72.

58. Toyokawa H, Matsui Y, Uhara J, Tsuchiya H, Teshima S, Nakanishi H, Kwon AH, et al. Promotive effects of far-infrared

ray on full-thickness skin wound healing in rats. *Exp Biol Med (Maywood)* 2003;228:724–9.

59. Capon A, Mordon S. Can thermal lasers promote skin wound healing? *Am J Clin Dermatol* 2003;4:1–12.

60. Lloyd BJ, Farkas BE, Keener KM. Characterization of radiant emitters used in food processing. *J Microw Power Electromagn Energy* 2003;38:213–24.

61. Honda K, Inoue S. Sleep-enhancing effects of far-infrared radiation in rats. *Int J Biometeorol* 1988;32:92–4.

62. Udagawa Y, Nagasawa H. Effects of far-infrared ray on reproduction, growth, behaviour and some physiological parameters in mice. *In Vivo* 2000;14:321–6.

63. Yu SY, Chiu JH, Yang SD, Hsu YC, Lui WY, Wu CW. Biological effect of far-infrared therapy on increasing skin microcirculation in rats. *Photodermatol Photoimmunol Photomed* 2006;22:78–86.

64. Akasaki Y, Miyata M, Eto H, Shirasawa T, Hamada N, Ikeda Y, Biro S, et al. Repeated thermal therapy up-regulates endothelial nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. *Circ J* 2006;70:463–70.

65. Imamura M, Biro S, Kihara T, Yoshifuku S, Takasaki K, Otsuji Y, Minagoe S, et al. Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. *J Am Coll Cardiol* 2001;38:1083–8.

66. Ikeda Y, Biro S, Kamogawa Y, Yoshifuku S, Eto H, Orihara K, Yu B, et al. Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. *Circ J* 2005;69:722–9.

67. Kihara T, Biro S, Ikeda Y, Yoshifuku S, Takasaki K, Otsuji Y, Minagoe S, et al. Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. *Circ J* 2004;68:1146–51.

68. Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. *J Am Soc Nephrol* 2007;18:985–92.

69. Hartel M, Hoffmann G, Wente MN, Martignoni ME, Buchler MW, Friess H. Randomized clinical trial of the influence of local water-filtered infrared A irradiation on wound healing after abdominal surgery. *Br J Surg* 2006;93:952–60.

70. Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, Durante W. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. *Arterioscler Thromb Vasc Biol* 2008;28:739–45.

71. Kipshidze N, Nikolaychik V, Muckerheidi M, Keelan MH, Chekanov V, Maternowski M, Chawla P, et al. Effect of short pulsed nonablative infrared laser irradiation on vascular cells *in vitro* and neointimal hyperplasia in a rabbit balloon injury model. *Circulation* 2001;104:1850–5.

72. Masuda A, Miyata M, Kihara T, Minagoe S, Tei C. Repeated sauna therapy reduces urinary 8-epi-prostaglandin F(2alpha). *Jpn Heart J* 2004;45:297–303.

73. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. *Arterioscler Thromb Vasc Biol* 1997;17:2309–15.